Fiche centre
Orlando Health Cancer Institute
Orlando — United States
Essais liés5clinical trials
VilleOrlandolocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06667908
Essais cliniques associés
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| JNJ-90301900 | Cancer | Phase 2 | NCT06667908 | CONVERGE — A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) | RECRUITING |
| Biopsy Procedure | SEP | Phase 2 | NCT02143414 | Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING |
| cemacabtagene ansegedleucel | SEP | Phase 2 | NCT06500273 | ALPHA3 — Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | RECRUITING |
| Obinutuzumab | Cancer | Phase 2 | NCT06806033 | A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT04267848 | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | RECRUITING |